Codexis, a leading provider of enzymatic solutions for efficient and scalable manufacturing of complex oligonucleotide therapeutics, shared new advances in RNA therapeutic manufacturing at TIDES USA ...

The discovery of siRNA and its role in RNAi was a groundbreaking finding in the field of molecular biology. In 1998, Andrew Fire and Craig Mello published a seminal paper describing the phenomenon of ...

Suzhou Ribo Life Science Co., Ltd. ("Ribo", 06938.HK) announced that the Company has entered into a strategic collaboration ...

Small interfering RNA (siRNA) drugs are a class of therapeutic agents that silence specific genes associated with inherited diseases. However, siRNA drugs have challenges because siRNAs often silence ...

SYDNEY--(BUSINESS WIRE)--Novotech, a globally recognized full-service clinical research organization (CRO) and scientific advisory company, has released its newest preclinical report exploring the ...

Founded in 1992, Sirna Therapeutics was one of the earliest biotechnology companies focused on developing therapeutics based on RNA interference (RNAi), specifically using small interfering RNA (siRNA ...

Chronic hepatitis B (CHB) remains a significant global health burden, with existing therapies including nucleos(t)ide analogs, interferon, siRNA, and therapeutic vaccines demonstrating limited success ...

As with its previous siRNA deal, Madrigal plans to explore whether gene-silencing could complement its lead drug Rezdiffra.

Two start-ups have launched to develop next-generation drugs using small interfering RNA (siRNA) to silence genes. The first, Judo Bio, is a spin-off of the venture capital firm Atlas Venture. The ...